Many people struggling with obesity, type 2 diabetes, or insulin resistance face a deeper challenge rooted in hormones, metabolism, and overall mental health
What the Research Actually Shows Honestly assessing the state of BPC-157 evidence: preclinical research demonstrates plausible biological mechanisms and tissue-level effects in animal models
In a phase 2 randomized clinical trial, it demonstrated a benefit in terms of resolution of MASH in patients with histologically proven MASH and stage 2 or 3 fibrosis. In his presentation, Newsome reported interim efficacy and safety results from the ongoing phase 3 ESSENCE trial, which is comparing once-weekly, subcutaneous semaglutide vs
This has led to growing interest in triple agonist therapies for: obesity, metabolic syndrome, insulin resistance, fatty liver disease, and body composition management
Three caveats matter: Bioavailability stays below injectable
Mir Ali, medical director at the MemorialCare Surgical Weight Loss Center